Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Montag A & Associates Inc.

Montag A & Associates Inc. reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,067 shares of the medical research company’s stock after selling 1,886 shares during the period. Montag A & Associates Inc.’s holdings in Edwards Lifesciences were worth $3,706,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $555,939,000. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after buying an additional 2,606,950 shares during the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $109,490,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $76.23 on Friday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $44.96 billion, a P/E ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. The firm’s 50 day moving average is $72.67 and its 200-day moving average is $69.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 in the last quarter. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent research reports. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Morgan Stanley upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Piper Sandler raised their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Truist Financial reissued a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.